MCID: ANL017
MIFTS: 46

Anal Squamous Cell Carcinoma malady

Categories: Gastrointestinal diseases, Cancer diseases, Skin diseases

Aliases & Classifications for Anal Squamous Cell Carcinoma

About this section

Aliases & Descriptions for Anal Squamous Cell Carcinoma:

Name: Anal Squamous Cell Carcinoma 11 13 68
Epidermoid Anal Carcinoma 11
 
Carcinoma of Anal Margin 68

Classifications:



External Ids:

Disease Ontology11 DOID:5525
SNOMED-CT62 255084004
NCIt45 C9161

Summaries for Anal Squamous Cell Carcinoma

About this section
Disease Ontology:11 An anal carcinoma that arises near the squamocolumnar junction.

MalaCards based summary: Anal Squamous Cell Carcinoma, also known as epidermoid anal carcinoma, is related to salivary gland adenoid cystic carcinoma and biliary papillomatosis. An important gene associated with Anal Squamous Cell Carcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways are Doxorubicin Pathway, Pharmacokinetics and Deactivation of the beta-catenin transactivating complex. Affiliated tissues include lymph node, breast and liver, and related mouse phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and pigmentation.

Related Diseases for Anal Squamous Cell Carcinoma

About this section

Diseases related to Anal Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 164)
idRelated DiseaseScoreTop Affiliating Genes
1salivary gland adenoid cystic carcinoma10.4CDKN2A, TP53
2biliary papillomatosis10.4CDKN2A, TP53
3epidural spinal canal angiolipoma10.4CDKN2A, MDM2
4split hand split foot malformation autosomal recessive10.4CDKN2A, TP53
5adenoid squamous cell carcinoma10.4CDKN2A, TP53
6simple partial epilepsy10.4CDKN2A, TP53
7cystoisosporiasis10.4CDKN2A, TP53
8vulva fibroepithelial polyp10.4CDKN2A, TP53
9localized chondrosarcoma10.4CDKN2A, MDM2
10oral pharyngeal disorders10.4CDKN2A, TP53
11ureter adenocarcinoma10.4CDKN2A, TP53
12sclerosing liposarcoma10.4CDKN2A, MDM2
13duodenum cancer10.4CDKN2A, TP53
14pityriasis versicolor10.4CDKN2A, TP53
15liver lymphoma10.4CDKN2A, TP53
16pleuropulmonary blastoma type 210.4CDKN2A, MDM2
17adenofibroma10.4CDKN2A, TP53
18herpes simplex10.4CDKN2A, TP53
19pancreatic agenesis10.4CDKN2A, TP53
20spastic ataxia 310.4CDKN2A, TP53
21esophagus verrucous carcinoma10.4CDKN2A, TP53
22malignant hyperthermia susceptibility10.3APC, TP53
23pituitary carcinoma10.3CDKN2A, TP53
24toxascariasis10.3CDKN2A, MDM2
25x-linked congenital generalized hypertrichosis10.3CDKN2A, TP53
26preeclampsia/eclampsia 310.3CDKN2A, TP53
27hereditary essential tremor 510.3APC, MLH1
28sulfhemoglobinemia10.3CDKN2A, TP53
29sialolithiasis10.3CDKN2A, TP53
30desmoplastic infantile astrocytoma10.3APC, CDKN2A
31mesenchymoma10.3CDKN2A, TP53
32hypersensitivity reaction type iv disease10.3CDKN2A, TP53
33submucosal invasive colon adenocarcinoma10.3CDKN2A, MLH1
34oligodendroglioma10.3CDKN2A, TP53
35epithelioid trophoblastic tumor10.3CDKN2A, TP53
36mucinous adenocarcinoma10.3APC, TP53
37cellular myxoid liposarcoma10.3CDKN2A, MDM2
38compartment syndrome10.3CDKN2A, TP53
39synchronous bilateral breast carcinoma10.3CDKN2A, TP53
40stroma-dominant and stroma-poor composite ganglioneuroblastoma10.3CDKN2A, TP53
41actinic keratosis10.3CDKN2A, TP53
42ductal carcinoma in situ10.3CDKN2A, TP53
43pelvic muscle wasting10.3CDKN2A, TP53
44chromosome 7p duplication10.3MDM2, TP53
45pyoderma10.3MLH1, TP53
46pasli disease10.3MDM2, TP53
47median neuropathy10.3MDM2, TP53
48multiple carboxylase deficiency10.3MDM2, TP53
49renal hypodysplasia10.3CDKN2A, TP53
50prostate calculus10.2MDM2, TP53

Graphical network of the top 20 diseases related to Anal Squamous Cell Carcinoma:



Diseases related to anal squamous cell carcinoma

Symptoms & Phenotypes for Anal Squamous Cell Carcinoma

About this section

GenomeRNAi Phenotypes related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00250-A-39.0MDM2, MGMT, MLH1, TP53

MGI Mouse Phenotypes related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

41 (show all 15)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00011869.4APC, CDKN2A, MDM2, TP53
2MP:00053819.1APC, CDKN2A, MDM2, MLH1, TP53
3MP:00053808.9AKT1, APC, CDKN2A, MDM2, TP53
4MP:00053708.9AKT1, APC, CDKN2A, MDM2, TP53
5MP:00053698.8AKT1, APC, CDKN2A, MDM2, TP53
6MP:00030128.6APC, CDKN2A, MDM2, MGMT, TP53
7MP:00053868.4AKT1, APC, CDKN2A, MDM2, MLH1, TP53
8MP:00053848.4AKT1, APC, CDKN2A, MDM2, MLH1, TP53
9MP:00107718.4AKT1, APC, CDKN2A, MDM2, MLH1, TP53
10MP:00053898.3AKT1, APC, CDKN2A, MDM2, MLH1, TP53
11MP:00053908.0AKT1, APC, CDKN2A, MDM2, TP53
12MP:00053797.6AKT1, APC, CDKN2A, MDM2, MGMT, MLH1
13MP:00053767.6AKT1, APC, CDKN2A, MDM2, MGMT, MLH1
14MP:00107687.6AKT1, APC, CDKN2A, MDM2, MGMT, MLH1
15MP:00020067.5AKT1, APC, CDKN2A, MDM2, MGMT, MLH1

Drugs & Therapeutics for Anal Squamous Cell Carcinoma

About this section

Drugs for Anal Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 78)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Imiquimodapproved, investigationalPhase 4, Phase 313899011-02-657469
Synonyms:
1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine
1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine
1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine
1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
1-isobutyl-1H-imidazo(4,5-c)quinolin-4-amine
1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
3M Brand of Imiquimod
4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline
4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline
99011-02-6
AC-529
AC1L1N2I
AC1Q4YO9
Aldara
Aldara (TN)
Aldara, Imiquimod
BB_SC-2107
BIDD:GT0859
Beselna
C056493
CHEBI:36704
CHEMBL1282
CID57469
D02500
DB00724
DZ-2636
FT-0080222
HMS2090M14
 
I06-0624
I06-2289
I0747
I5159_SIGMA
IMIQUIMOD
Imiquimod
Imiquimod (JAN/USAN/INN)
Imiquimod [USAN:INN]
Imiquimod acetate
Imiquimodum
LS-178395
MLS000083577
MTD-39
MolPort-002-507-845
NCGC00070736-02
NSC369100
R 837
R-837
S 26308
S-26308
S1211_Selleck
SMR000048307
STK583860
TL8006059
TMX-101
UNII-P1QW714R7M
ZINC19632912
Zartra
Zyclara
imiquimod
2AntibodiesPhase 4, Phase 2, Phase 16045
3ImmunoglobulinsPhase 4, Phase 2, Phase 16045
4VaccinesPhase 4, Phase 16428
5Adjuvants, ImmunologicPhase 4, Phase 3, Phase 12484
6interferonsPhase 4, Phase 32137
7Interferon InducersPhase 4, Phase 3285
8
FluorouracilapprovedPhase 3, Phase 2, Phase 1, Early Phase 1179151-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
9
CisplatinapprovedPhase 3, Phase 2269015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
10
Paclitaxelapproved, vet_approvedPhase 3, Phase 2, Phase 1275833069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nab-paclitaxel
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
11
Capecitabineapproved, investigationalPhase 3, Phase 21296154361-50-960953
Synonyms:
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
CAPECITABINE
CHEBI:31348
CHEMBL1773
CID60953
Capecitabin
Capecitabina
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
 
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
capecitabina
capecitabine
capecitabinum
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
12
Fentanylapproved, illicit, investigational, vet_approvedPhase 3773437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
1-phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl CII
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
 
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
13MitomycinsPhase 3, Phase 2, Phase 1, Early Phase 1233
14Liver ExtractsPhase 3, Phase 2, Phase 13868
15Immunosuppressive AgentsPhase 3, Phase 2, Phase 1, Early Phase 112770
16Antimetabolites, AntineoplasticPhase 3, Phase 2, Early Phase 17171
17AntimetabolitesPhase 3, Phase 2, Early Phase 111774
18pancreatic polypeptidePhase 320
19NarcoticsPhase 33486
20Albumin-Bound PaclitaxelPhase 3, Phase 2, Phase 12757
21Antineoplastic Agents, PhytogenicPhase 3, Phase 2, Phase 15420
22Antimitotic AgentsPhase 3, Phase 2, Phase 15498
23Peripheral Nervous System AgentsPhase 3, Phase 222776
24Anesthetics, IntravenousPhase 32406
25Adjuvants, AnesthesiaPhase 31588
26Nucleic Acid Synthesis InhibitorsPhase 3, Phase 2, Early Phase 14855
27Antibiotics, AntitubercularPhase 3, Phase 2, Early Phase 16972
28Alkylating AgentsPhase 3, Phase 2, Early Phase 14694
29AnalgesicsPhase 311287
30Anti-Bacterial AgentsPhase 3, Phase 2, Phase 1, Early Phase 110884
31Central Nervous System DepressantsPhase 312806
32Anesthetics, GeneralPhase 32787
33AnestheticsPhase 39001
34Analgesics, OpioidPhase 33091
35ColaNutraceuticalPhase 3, Phase 2, Phase 11881
36
IndinavirapprovedPhase 2110150378-17-95362440
Synonyms:
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-pentonamide
(2S)-1-[(2S,4S)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
150378-17-9
157810-81-6
157810-81-6 (sulfate (1:1) (salt))
166746-42-5
1c6y
1hsg
1hsh
1k6c
1sdt
1sdu
1sdv
1sgu
216884-06-9
2avo
2avs
2avv
2bpx
AC-20034
AC1L1U7I
AKOS000280989
BIDD:GT0378
BIDD:PXR0141
C07051
 
C36H47N5O4
CHEBI:44032
Compound J
Crixivan
Crixivan (TM)
DB00224
IDV
Indinavir (*1:1 Sulfate salt*)
Indinavir [USAN]
Indinavir anhydrous
Indinavir sulfate
Indinavir sulphate
Indinavir, Sulfate (1:1)
L 735524
L-735 524
L-735,524
L-735524
LS-173382
MK-639
MolPort-000-883-804
N-[2(R)-HYDROXY-1(S)-INDANYL]-5-[(2(S)-TERTIARY BUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE
NCGC00159460-02
NSC697197
Propolis & 4-Hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyl]hexanediamide
Propolis+Indinavir
RS-253
UNII-9MG78X43ZT
indinavir
37
Ritonavirapproved, investigationalPhase 2870155213-67-5392622
Synonyms:
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
155213-67-5
1hxw
1sh9
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
538, ABT
A-84538
ABBOTT-84538
ABT 538
ABT 84538
ABT-538
ABT538
AC-733
AC1L94GB
AKOS000280930
Abbott 84538
BIDD:GT0387
BIDD:PXR0023
Bio-0093
C07240
C37H48N6O5S2
CHEBI:45409
CHEMBL163
CID392622
CPD000466395
D00427
D019438
 
DB00503
DRG-0244
FT-0082824
HMS2051B08
HSDB 7160
LS-148860
MLS000759541
MLS001424063
MolPort-000-883-877
N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide
NCGC00159462-02
NSC693184
Norvir
Norvir (TM)
Norvir (TN)
Norvir Sec
RIT
RTV
Ritonavir
Ritonavir (JAN/USAN/INN)
Ritonavir [USAN]
Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.
Ritonavirum
S1185_Selleck
SAM001246783
SMR000466395
STK634209
ZINC03944422
ritonavir
38
CetuximabapprovedPhase 2, Phase 1737205923-56-456842117, 2333
Synonyms:
205923-56-4
Anti EGFR
Cetuximab
Cetuximab (USAN/INN)
Cetuximab (genetical recombination)
Cetuximab (genetical recombination) (JAN)
 
Cetuximabum
Cétuximab
D03455
Erbitux
Erbitux (TN)
IMC-C225
Immunoglobulin G 1 (human-mouse monoclonal C 225 gamma 1 - chain anti-human epidermal growt factor receptor), disulfide wit human-mouse monoclonal C 225 kappa - chain, dimer
cetuximab
39
Oxaliplatinapproved, investigationalPhase 2141261825-94-35310940, 9887054, 43805, 6857599, 9887054
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
 
Oxalatoplatinum
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
oxaliplatine
oxaliplatino
oxaliplatinum
40
CarboplatinapprovedPhase 2, Phase 1198041575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
41
PembrolizumabapprovedPhase 24211374853-91-4
Synonyms:
Keytruda
 
MK-3475
lambrolizumab
42
nivolumabapprovedPhase 2, Phase 1326946414-94-4
Synonyms:
BMS-936558
 
MDX-1106
ONO-4538
nivolumab
43
SuccinylcholineapprovedPhase 2161306-40-15314
Synonyms:
2,2'-[(1,4-DIOXOBUTANE-1,4-DIYL)BIS(OXY)]BIS(N,N,N-TRIMETHYLETHANAMINIUM)
2,2'-[(1,4-DIOXOBUTANE-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)
2ha2
2ha6
306-40-1
4-04-00-01451 (Beilstein Handbook Reference)
541-19-5 (diiodide)
55-94-7 (dibromide)
71-27-2 (dichloride)
AC1L1K2T
Anectine
BRN 1805311
C07546
C14H30N2O4
CHEBI:45652
CHEMBL703
CID5314
Choline, succinate (2:1) (ester)
Choline, succinate (ester)
DB00202
Diacetylcholine
Dicholine succinate
Ditilin
Ditiline
HMS2090P14
HSDB 3254
InChI=1/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2
L000926
LS-53328
Listenon
 
Lopac-S-8251
Lopac0_001080
Lysthenon
MolPort-002-964-486
NCGC00015971-01
NCGC00015971-03
NCGC00162336-01
Quelicin
Quelicin Preservative Free
SCK
ST50437287
STK177290
Scoline
Succicuran
Succinic acid, diester with choline
Succinic acid, diester with choline chloride
Succinocholine
Succinoylcholine
Succinyl choline
Succinylbischoline
Succinylcholine
Succinylcholine Chloride
Succinyldicholine
Sucostrin
Suxamethonium
Suxamethonium chloride
UNII-J2R869A8YF
ZINC01530820
succinylcholine
succinyldicholine
trimethyl-[2-[4-oxo-4-(2-trimethylazaniumylethoxy)butanoyl]oxyethyl]azanium diio
trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium
44
Docetaxelapproved, investigational, Approved May 1996Phase 2, Phase 11918114977-28-5148124, 9877265
Synonyms:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
01885_FLUKA
114977-28-5
4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC-383
AC1L3WHJ
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
Docetaxel
Docetaxel (INN)
Docetaxel anhydrous
Docetaxel, Trihydrate
EmDOC
 
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
TXL
Taxotere
Taxotere (TN)
Taxotere(R)
XRP-6976L
docetaxel
docetaxel 114977-28-5
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
45
protease inhibitorsPhase 25320
Synonyms:
 
protease inhibitors
46Anti-Infective AgentsPhase 2, Phase 121402
47HIV Protease InhibitorsPhase 25319
48Anti-HIV AgentsPhase 23100
49Antiviral AgentsPhase 29732
50Antibodies, MonoclonalPhase 2, Phase 13795

Interventional clinical trials:

(show top 50)    (show all 60)
idNameStatusNCT IDPhase
1Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant RecipientsActive, not recruitingNCT02624349Phase 4
2Anal Dysplasia Study of Men Who Have Sex With Men Living With HIVWithdrawnNCT01663558Phase 4
3Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal CancerUnknown statusNCT00003652Phase 3
4Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal CancerCompletedNCT00003596Phase 3
5Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal CancerCompletedNCT00025090Phase 3
6Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
7Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard RadiochemotherapyRecruitingNCT02369939Phase 3
8Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin LesionsRecruitingNCT02059499Phase 3
9Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma PatientsNot yet recruitingNCT02526953Phase 3
10Fluorescence for Sentinel Lymph Node Identification in Cancer SurgeryNot yet recruitingNCT02997553Phase 3
11Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal CancerTerminatedNCT00068744Phase 2, Phase 3
12Vectibix for the Treatment of Anal CancerUnknown statusNCT01285778Phase 2
13Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal CancerUnknown statusNCT00955240Phase 2
14External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain MetastasesUnknown statusNCT00637637Phase 2
15Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal CancerCompletedNCT00324415Phase 2
16A Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal.CompletedNCT01941966Phase 2
17Oral Rigosertib for Squamous Cell CarcinomaCompletedNCT01807546Phase 2
18Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal CancerCompletedNCT00093379Phase 2
19Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the AnusRecruitingNCT01581840Phase 1, Phase 2
20Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal CarcinomaRecruitingNCT02402842Phase 2
21International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly PaclitaxelRecruitingNCT02051868Phase 2
22Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV InfectionRecruitingNCT02437851Phase 2
23Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal CancerRecruitingNCT02560298Phase 2
24Phase 2 Study of ADXS11-001 in Subjects With Carcinoma of the Anorectal CanalRecruitingNCT02399813Phase 2
25Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)RecruitingNCT02628067Phase 2
26Genetic Predictors of Benefit to PembrolizumabRecruitingNCT02710396Phase 2
27Nivolumab and Ipilimumab in Treating Patients With Rare TumorsRecruitingNCT02834013Phase 2
28Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal CancerActive, not recruitingNCT00316888Phase 2
29Nivolumab in Treating Patients With Refractory Metastatic Anal Canal CancerActive, not recruitingNCT02314169Phase 2
30Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal CancerActive, not recruitingNCT00423293Phase 2
31Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By SurgeryActive, not recruitingNCT00331760Phase 2
32Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal CanalTerminatedNCT01843452Phase 2
33Nimotuzumab With Radiotherapy in the Treatment of Anal Canal CancersTerminatedNCT01382745Phase 2
34A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the AnusWithdrawnNCT02857608Phase 2
35A Phase 1 Study in Participants With Advanced CancerCompletedNCT01115790Phase 1
36Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.CompletedNCT00423254Phase 1
37Vaccine Therapy in Treating Patients With Advanced or Recurrent CancerCompletedNCT00019110Phase 1
38Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
39Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerCompletedNCT00397384Phase 1
407-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
41Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
42MS-275 in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00020579Phase 1
43Thalidomide and Docetaxel in Treating Patients With Advanced CancerCompletedNCT00049296Phase 1
44HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIARecruitingNCT02379520Phase 1
45Nivolumab and Ipilimumab in Treating Patients With HIV Associated Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryRecruitingNCT02408861Phase 1
46Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV InfectionActive, not recruitingNCT01249443Phase 1
47Anal Dysplasia in Patients With Inflammatory Bowel DiseaseUnknown statusNCT01653054
48Molecular Biology of Anal Cancer in HIV-Positive PatientsCompletedNCT00952874
49OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With CancerCompletedNCT00900302
50Videoscopic Versus Open Inguinal Lymphadenectomy for CancerCompletedNCT01526486

Search NIH Clinical Center for Anal Squamous Cell Carcinoma

Genetic Tests for Anal Squamous Cell Carcinoma

About this section

Anatomical Context for Anal Squamous Cell Carcinoma

About this section

MalaCards organs/tissues related to Anal Squamous Cell Carcinoma:

36
Lymph node, Breast, Liver, Skin, Kidney, Brain, Lung

Publications for Anal Squamous Cell Carcinoma

About this section

Articles related to Anal Squamous Cell Carcinoma:

(show top 50)    (show all 73)
idTitleAuthorsYear
1
Chemoradiotherapy for anal squamous cell carcinoma. (27118047)
2016
2
A Patient with HIV-Associated Metastatic Anal Squamous Cell Carcinoma Receiving Multimodality Therapy with Curative Intent: Case Report and Review of the Literature. (26961789)
2016
3
Genomic evolution after chemoradiotherapy in anal squamous cell carcinoma. (27852700)
2016
4
A Prolapsing Pile Revealing Anal Squamous Cell Carcinoma. (27125703)
2016
5
A combined modality therapeutic approach to metastatic anal squamous cell carcinoma with systemic chemotherapy and local therapy to sites of disease: case report and review of literature. (27284490)
2016
6
Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes. (27052656)
2016
7
Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma. (25984929)
2016
8
Metastatic rectal adenocarcinoma and anal squamous cell carcinoma masquerading as vulvar lymphangioma circumscriptum. (27616148)
2016
9
Anal squamous cell carcinoma in Crohn's disease. (27773118)
2016
10
Anal Squamous Cell Carcinoma: An Infrequent Challenge in the Management of Ulcerative Colitis Under Combination Therapy. (26818664)
2016
11
High-sensitivity human papilloma virus genotyping reveals near universal positivity in anal squamous cell carcinoma: Different implications for vaccine prevention and prognosis. (25702585)
2015
12
Concomitant Chemoradiotherapy with Cisplatin Plus 5-Fluorouracil for Anal Squamous Cell Carcinoma. (25810165)
2015
13
Anal squamous cell carcinoma in chronic severe perianal Crohn's disease. (25702309)
2015
14
Tumor-infiltrating CD8(+) T lymphocytes associated with clinical outcome in anal squamous cell carcinoma. (26287957)
2015
15
A tumor control probability model for anal squamous cell carcinoma. (26243680)
2015
16
Molecular biology of anal squamous cell carcinoma: implications for future research and clinical intervention. (26678214)
2015
17
Human papillomavirus in anal squamous cell carcinoma: an angel rather than a devil? (25987898)
2015
18
Human papillomavirus DNA load and p16(INK4a) expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy. (24839133)
2015
19
Anal Squamous Cell Carcinoma in African Americans with and without HIV: A Comparative Study. (27774311)
2015
20
Grade 4 radiation dermatitis presenting with full-thickness ulcerations of the groin after radiation therapy for anal squamous cell carcinoma (SCC): An example of the "bolus effect" of radiation therapy. (27051789)
2015
21
Anal squamous cell carcinoma: an evolution in disease and management. (25278699)
2014
22
Anal squamous cell carcinoma in HIV/AIDS patients in the HAART era: Report of 8 cases and literature review. (26753381)
2014
23
Prognostic value of human papillomavirus in anal squamous cell carcinoma. (25209946)
2014
24
Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma. (24885554)
2014
25
Atypical pelvic recurrence of anal squamous cell carcinoma: successful endoscopic ultrasound-guided fine-needle aspiration through the sigmoid colon. (24997718)
2014
26
Cutaneous vulvar metastases in a patient with anal squamous cell carcinoma. (23617081)
2013
27
Aggressive strategy for the treatment of synchronous metastatic anal squamous cell carcinoma. (23958077)
2013
28
Outcome of salvage surgery for anal squamous cell carcinoma. (23522325)
2013
29
When rectal bleeding is serious: anal squamous cell carcinoma in two intravenous cyclophosphamide treated systemic lupus erythematosus patients with human papilloma virus infection. (23893826)
2013
30
A systematic review of anal squamous cell carcinoma in inflammatory bowel disease. (24050823)
2013
31
Systematic review of sentinel lymph node biopsy in anal squamous cell carcinoma. (23872032)
2013
32
Salvage Surgery for Residual Primary and Locally Recurrent Anal Squamous Cell Carcinoma After Chemoradiotherapy in HIV-positive Individuals. (24242676)
2013
33
Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis. (23692961)
2013
34
Development of cerebral metastasis after medical and surgical treatment of anal squamous cell carcinoma. (23091760)
2012
35
Management of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapy. (25031942)
2012
36
Advanced anal squamous cell carcinoma -- radiotherapy or surgery? (23116837)
2012
37
Early clinical outcomes of anal squamous cell carcinoma treated with concurrent chemoradiotherapy with 5-Fluorouracil plus mitomycin C in Japanese patients: experience at a single institution. (22717459)
2012
38
Evaluation of Langerhans cells counts comparing HIV-positive and negative anal squamous cell-carcinoma patients. (23033134)
2012
39
Current treatment of anal squamous cell carcinoma. (23116582)
2012
40
The prognostic significance of tumor human papillomavirus status for patients with anal squamous cell carcinoma treated with combined chemoradiotherapy. (21128253)
2011
41
Metachronous splenic metastasis in an anal squamous cell carcinoma. (21563664)
2011
42
The role of A^a8,fluoro-deoxy glucose combined position emission and computed tomography in the clinical management of anal squamous cell carcinoma. (20070338)
2011
43
Chemoradiation for anal squamous cell carcinoma: case report. (22018257)
2011
44
Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinoma. (21291546)
2011
45
Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978-2005. (19960431)
2010
46
Radiation therapy of recurrent anal squamous cell carcinoma in-situ: a case report. (20181236)
2010
47
Current therapeutic strategies for anal squamous cell carcinoma in Japan. (19856049)
2009
48
Anal squamous cell carcinoma in the HIV-positive patient. (20436834)
2009
49
Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma. (19330178)
2009
50
Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy. (18066626)
2008

Variations for Anal Squamous Cell Carcinoma

About this section

Expression for genes affiliated with Anal Squamous Cell Carcinoma

About this section
Search GEO for disease gene expression data for Anal Squamous Cell Carcinoma.

Pathways for genes affiliated with Anal Squamous Cell Carcinoma

About this section

Pathways related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 49)
idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
9.5MLH1, TP53
29.4AKT1, APC
39.4MDM2, TP53
4
Show member pathways
9.4MDM2, TP53
5
Show member pathways
9.3AKT1, TP53
6
Show member pathways
9.3AKT1, TP53
79.3AKT1, TP53
8
Show member pathways
9.2MGMT, MLH1
99.1CDKN2A, MDM2, TP53
109.1CDKN2A, MDM2, TP53
11
Show member pathways
9.1CDKN2A, MDM2, TP53
129.1CDKN2A, MDM2, TP53
13
Show member pathways
9.1CDKN2A, MDM2, TP53
14
Show member pathways
9.1CDKN2A, MDM2, TP53
159.1CDKN2A, MDM2, TP53
16
Show member pathways
9.1CDKN2A, MDM2, TP53
179.1CDKN2A, MDM2, TP53
189.1CDKN2A, MDM2, TP53
199.1CDKN2A, MDM2, TP53
208.9AKT1, APC, TP53
21
Show member pathways
8.8AKT1, MDM2, TP53
22
Show member pathways
8.8AKT1, MDM2, TP53
238.8AKT1, MDM2, TP53
24
Show member pathways
8.8AKT1, MDM2, TP53
258.8AKT1, MDM2, TP53
26
Show member pathways
8.8AKT1, MDM2, TP53
278.8AKT1, MDM2, TP53
288.8AKT1, MDM2, TP53
29
Show member pathways
8.8AKT1, MDM2, TP53
30
Show member pathways
8.8AKT1, MDM2, TP53
318.8AKT1, MDM2, TP53
328.8AKT1, MDM2, TP53
338.8AKT1, MDM2, TP53
34
Show member pathways
8.8AKT1, MDM2, TP53
358.6APC, CDKN2A, MDM2, TP53
368.6APC, MDM2, MLH1, TP53
378.5AKT1, APC, CDKN2A, TP53
388.5AKT1, APC, MLH1, TP53
39
Show member pathways
8.4AKT1, CDKN2A, MDM2, TP53
40
Show member pathways
8.4AKT1, CDKN2A, MDM2, TP53
41
Show member pathways
8.4AKT1, CDKN2A, MDM2, TP53
42
Show member pathways
8.4AKT1, CDKN2A, MDM2, TP53
438.4AKT1, APC, MDM2, TP53
44
Show member pathways
8.0AKT1, CDKN2A, MDM2, MLH1, TP53
45
Show member pathways
7.9AKT1, APC, MDM2, MLH1, TP53
467.8CDKN2A, MDM2, MGMT, MLH1, TP53
477.6AKT1, APC, CDKN2A, MDM2, MLH1, TP53
487.2AKT1, APC, CDKN2A, MDM2, MGMT, TP53
49
Show member pathways
7.2AKT1, CDKN2A, MDM2, MGMT, MLH1, TP53

GO Terms for genes affiliated with Anal Squamous Cell Carcinoma

About this section

Cellular components related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1nuclear bodyGO:001660410.3MDM2, TP53
2nucleoplasmGO:00056547.9AKT1, APC, MDM2, MGMT, MLH1, TP53
3nucleusGO:00056346.7AKT1, APC, CDKN2A, MDM2, MGMT, MLH1

Biological processes related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 15)
idNameGO IDScoreTop Affiliating Genes
1negative regulation of cyclin-dependent protein serine/threonine kinase activityGO:004573610.4APC, CDKN2A
2cellular response to nerve growth factor stimulusGO:199009010.2AKT1, APC
3positive regulation of protein export from nucleusGO:004682710.0MDM2, TP53
4replicative senescenceGO:009039910.0CDKN2A, TP53
5cell cycle arrestGO:00070509.9APC, CDKN2A, TP53
6cellular response to ionizing radiationGO:00714799.8MGMT, TP53
7mammary gland epithelial cell differentiationGO:00606449.7AKT1, MGMT
8protein complex assemblyGO:00064619.6APC, MDM2, TP53
9positive regulation of apoptotic processGO:00430659.5AKT1, APC, TP53
10cellular response to hypoxiaGO:00714569.5AKT1, MDM2, TP53
11response to antibioticGO:00466779.4MDM2, TP53
12regulation of signal transduction by p53 class mediatorGO:19017969.2AKT1, MDM2, TP53
13cellular response to organic cyclic compoundGO:00714079.2AKT1, MDM2, MGMT
14negative regulation of apoptotic processGO:00430668.7AKT1, MDM2, MGMT, TP53
15cellular response to DNA damage stimulusGO:00069748.4AKT1, APC, MGMT, MLH1, TP53

Molecular functions related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protein phosphatase 2A bindingGO:00517219.3AKT1, TP53
2protein kinase bindingGO:00199018.9AKT1, APC, CDKN2A, TP53

Sources for Anal Squamous Cell Carcinoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet